Finn et al. reported the combination therapy of atezolizumab (anti-PD-L1) and bevacizumab, which is a vascular endothelial growth factor A (VEGF-A) inhibitor, as compared to sorafenib targeting anti-angiogenesis multikinase receptor, with statistically significant and clinically meaningful improvement in both OS and PFS in the treatment of unresectable HCC [14]. Here, VEGFA is linked to hepatocellular carcinoma.